Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen

Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen

Company Announcement

  *Genmab reaches key milestone in DuoBody® platform collaboration with
  *$2 million milestone payment to Genmab

COPENHAGEN, Denmark, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today it has reached a key milestone in its DuoBody
technology platform collaboration with Janssen Biotech, Inc. and its
affiliates ("Janssen"), triggering a $ 2 million payment. The milestone is for
achieving technical proof-of-concept for the first DuoBody product candidate.

Under the agreement, Janssen has the right to use the DuoBody technology to
create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple
disease target combinations with Genmab research funded by Janssen. Genmab
received an upfront payment of $3.5 million (approx. DKK 21 million on the
date of the agreement) from Janssen in July 2012 and will potentially be
entitled to milestone and license payments of up to approximately $175 million
(approx. DKK 1,062 million on the date of the agreement), as well as royalties
for each DuoBody product.

"We are pleased to reach an important proof-of-concept milestone for one of
the DuoBody products we are creating in our collaboration with Janssen and are
satisfied with the excellent progress we've made so far," said Jan van de
Winkel, Ph.D., Chief Executive Officer of Genmab.

Today's news will not have a material impact on Genmab's 2012 financial

About the DuoBody Platform

The DuoBody platform is an innovative platform for the discovery and
development of bispecific antibodies that may improve antibody therapy of
cancer, autoimmune, infectious and central nervous system disease. Bispecific
antibodies bind to two different epitopes either on the same, or on different
targets (also known as dual-targeting) which may improve the antibodies'
specificity and efficacy in inactivating the disease targets. DuoBody
molecules are unique in combining the benefits of bispecificity with the
strengths of conventional antibodies which allows DuoBody molecules to be
administered and dosed as other antibody therapeutics. Genmab's DuoBody
platform generates bispecific antibodies via a fast and broadly applicable
process which is easily performed at standard bench, as well as commercial,
manufacturing scale.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit


Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
T: +45 33 44 77 20; M: +45 25 12 62 60; E:

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab^(r); the Y-shaped Genmab logo^(r); HuMax^(r); HuMax-CD20^(r);
DuoBody^(r)and UniBody^(r)are all trademarks of Genmab A/S. Arzerra^(r) is a
trademark of GlaxoSmithKline.

Company Announcement no. 37
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Press spacebar to pause and continue. Press esc to stop.